QUICK READ:

• AbbVie, Humira’s manufacturer, kicked off 2020 with a price increase in excess of 7 percent on its mega-blockbuster brand-name treatment.
• The increase followed total Humira price hikes of 19 percent during 2017 and 2018.
• The cost of Humira, which is injected via syringe, was more than $72,000 a year on prescription drug websites this week and is not expected to come down until at least 2023.
• AbbVie won dozens of additional patents — what critics call a “patent thicket” — that extended the exclusive market for the drug.
• The top six executives at AbbViw make over $56.6 million.